Fig. 8.

Diosgenin (DG) promotes diabetic wound (DW) healing in vivo. To validate the in vivo effect of DG, mice were randomly divided into six groups: a non-diabetic control group (Control), a DW group (DW), and four diabetic treatment groups receiving either a low dose of DG (DW + DG^L), a high dose of DG (DW + DG^H), Fer-1 (DW + Fer-1), and a high dose of DG with OSS_128167 (DW + DG^H + OSS_128167). group (DW), and four diabetic treatment groups receiving either a low dose of DG (DW + DG^L), a high dose of DG (DW + DG^H), Fer-1 (DW + Fer-1), and a high dose of DG with OSS_128167 (DW + DG^H + OSS_128167). (A) Overview of the animal experiment. (B, C) Wound images during the healing process (B) and a schematic diagram of the wound healing process (C). (D) Quantitative data of wound area relative to day 0 for the 6 groups. (E−G) hematoxylin-eosin (H&E) (E) and quantitative analysis (F), Masson's trichrome staining images (G) of wound length. Results are presented as the mean ± standard deviation (SD) from quintuple tests, n ≥ 5. Significance is denoted as ^∗∗∗P < 0.001; ns indicates no significant difference. STZ: streptozocin.